Fomivirsen for the treatment of cytomegalovirus retinitis (Q77876177)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

editorial

0 references

title

Fomivirsen for the treatment of cytomegalovirus retinitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

cytomegalovirus retinitis

8 December 2019

main subject

1 reference

Douglas A Jabs

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Paul D Griffiths

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

language of work or name

English

0 references

publication date

1 April 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Ophthalmology

8 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

volume

133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

page(s)

552-556

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression

8 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

AIDS and ophthalmology: a period of transition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Prevalence of antiviral drug resistance in untreated patients with cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Cli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901325-9

10.1016/S0002-9394(02)01325-9

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11931791%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference